Reading...
Play button
Play button
Use LEFT and RIGHT arrow keys to navigate between flashcards;
Use UP and DOWN arrow keys to flip the card;
H to show hint;
A reads text to speech;
11 Cards in this Set
- Front
- Back
|
Eculizumab
|
Eculizumab is a humanized monoclonal IgG antibody that binds to COMPLEMENT PROTEIN C5, preventing cleavage into C5a and C5b.
USE: Treatment of paroxysmal nocturnal hemoglobinuria (PNH) to reduce hemolysis USE: Treatment of paroxysmal nocturnal hemoglobinuria (PNH) to reduce hemolysis |
|
|
Zileuton
|
FORMATION INHIBITOR
Anti - Leukotriene Specific 5-lipoxygenase inhibitor which inhibits leukotriene formation (Prophylaxis and chronic treatment of asthma) |
|
|
Montelukast & Zafirlukast
|
LT-RA
blocks leukotriene receptor occupation that’s correlated with the pathophysiology of asthma, |
|
|
CLASS and MOA of:
Cromolyn Nedocromil Lodoxamide |
Inhibits IgE from binding to its receptor on Mast cells which prevents degranulation and thus inflammation and smoothmuscle contraction
|
|
|
How do NSAIDS work to decrease fever?
|
NSAIDS inhibit prostaglandin synthesis
|
|
|
Muromonab-CD3
|
Reverses graft rejection by binding to T cells and interfering with their function and preventing activation by binding T-cell receptor-associated CD3 glycoprotein.
Now only the TCR can bind but not CD3 = not enough to activate Tcell |
|
|
Basiliximab (Simulect®)
|
Directed against the interleukin-2 receptor α-chain (IL-2Rα) preventing stim of T-cell clones by blocking IL-2 receptors
Alpha subunit also referred to as CD25 or Tac subunit |
|
|
Sirolimus (Rapamune®)
|
Sirolimus binds to FKBP-12, an intracellular protein, to form an immunosuppressive complex which inhibits the regulatory kinase, mTOR (mammalian target of rapamycin)
This inhibition suppresses cytokine mediated T-cell proliferation, halting progression from the G1 to the S phase of the cell cycle. |
|
|
Targets - name the drugs
CD3 CD20 CD80/86 Integrin IL-6 IL-2 |
CD3 Muromonab-CD3
CD20 - Rituximab CD80/86 - Abatacept: Selective costimulation modulator; inhibits T-cell (T-lymphocyte) activation by binding to CD80 and CD86 on antigen presenting cells (APC), thus blocking the required CD28 interaction between APCs and T cells Integrin-Natalizumab IL-6 receptor-Tocilizumab IL-2 receptor-Basiliximab |
|
|
Intracellular initiation disruption
Name the drugs: Purine synthesis inhibitor Pyrimidine synthesis inhbitor Antifolate Calcineurin Ihnibitor IL-1 receptor antagonist mTOR inhibitor mTOR inhibitor |
Purine synthesis inhibitor-Azathioprine, Mycophenolate
Pyrimidine synthesis inhbitor-Leflunomide Antifolate-Methotrexate Calcineurin Ihnibitor-Cyclosporine, Tacrolimus IL-1 receptor antagonist-Anakinra mTOR inhibitor-Sirolimus, Everolimus |
|
|
Vaccines - name type
TB- Typhoid- HepA-inactivated Influenza-inactivated Measles-attenuated Rubella- Yellow fever- varicella zoster- Hep B- |
Vaccines - name type
TB-attenuated Typhoid-attenuated HepA-inactivated Influenza-inactivated Measles-attenuated Rubella-inactivated Yellow fever-attenuated varicella zoster-attenuated Hep B-recombinant surface antigen |
